Literature DB >> 26557227

Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Patients with Heart Failure.

Loretta Fala1.   

Abstract

Entities:  

Year:  2015        PMID: 26557227      PMCID: PMC4636283     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN: 1942-2962


× No keyword cloud information.
  4 in total

1.  Heart disease and stroke statistics--2015 update: a report from the American Heart Association.

Authors:  Dariush Mozaffarian; Emelia J Benjamin; Alan S Go; Donna K Arnett; Michael J Blaha; Mary Cushman; Sarah de Ferranti; Jean-Pierre Després; Heather J Fullerton; Virginia J Howard; Mark D Huffman; Suzanne E Judd; Brett M Kissela; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Simin Liu; Rachel H Mackey; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Paul Muntner; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Graham Nichol; Latha Palaniappan; Dilip K Pandey; Mathew J Reeves; Carlos J Rodriguez; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Joshua Z Willey; Daniel Woo; Robert W Yeh; Melanie B Turner
Journal:  Circulation       Date:  2014-12-17       Impact factor: 29.690

2.  Lifetime costs of medical care after heart failure diagnosis.

Authors:  Shannon M Dunlay; Nilay D Shah; Qian Shi; Bruce Morlan; Holly VanHouten; Kirsten Hall Long; Véronique L Roger
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2010-12-07

3.  Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association.

Authors:  Paul A Heidenreich; Nancy M Albert; Larry A Allen; David A Bluemke; Javed Butler; Gregg C Fonarow; John S Ikonomidis; Olga Khavjou; Marvin A Konstam; Thomas M Maddox; Graham Nichol; Michael Pham; Ileana L Piña; Justin G Trogdon
Journal:  Circ Heart Fail       Date:  2013-04-24       Impact factor: 8.790

4.  Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Authors:  John J V McMurray; Milton Packer; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile
Journal:  N Engl J Med       Date:  2014-08-30       Impact factor: 91.245

  4 in total
  13 in total

Review 1.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

2.  Differential effects of low-dose sacubitril and/or valsartan on renal disease in salt-sensitive hypertension.

Authors:  Iuliia Polina; Mark Domondon; Rebecca Fox; Anastasia V Sudarikova; Miguel Troncoso; Valeriia Y Vasileva; Yuliia Kashyrina; Monika Beck Gooz; Ryan S Schibalski; Kristine Y DeLeon-Pennell; Wayne R Fitzgibbon; Daria V Ilatovskaya
Journal:  Am J Physiol Renal Physiol       Date:  2020-05-28

Review 3.  Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor.

Authors:  Ramesh R Dargad; Mahesh R Prajapati; Rohit R Dargad; Jai D Parekh
Journal:  Indian Heart J       Date:  2018-01-08

Review 4.  Recent advances in improving oral drug bioavailability by cocrystals.

Authors:  Shahram Emami; Mohammadreza Siahi-Shadbad; Khosro Adibkia; Mohammad Barzegar-Jalali
Journal:  Bioimpacts       Date:  2018-05-31

5.  Efficacy and safety of sacubitril/valsartan in the treatment of heart failure: protocol for a systematic review incorporating unpublished clinical study reports.

Authors:  David Byrne; Tom Fahey; Frank Moriarty
Journal:  HRB Open Res       Date:  2021-04-01

6.  Hospitalization Rates in Patients with Heart Failure and Reduced Ejection Fraction Initiating Sacubitril/Valsartan or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers: A Retrospective Cohort Study.

Authors:  Emma Houchen; Emil Loefroth; Raymond Schlienger; Clare Proudfoot; Stefano Corda; Sibasish Saha; Sarvesh K Satwase; Rachel Studer
Journal:  Cardiol Ther       Date:  2022-01-29

7.  Improving the solubility and bioavailability of anti-hepatitis B drug PEC via PEC-fumaric acid cocrystal.

Authors:  Long Li; Xian-Hong Yin; Kai-Sheng Diao
Journal:  RSC Adv       Date:  2020-10-02       Impact factor: 4.036

Review 8.  Drug-drug cocrystals: Opportunities and challenges.

Authors:  Xiaojuan Wang; Shuzhang Du; Rui Zhang; Xuedong Jia; Ting Yang; Xiaojian Zhang
Journal:  Asian J Pharm Sci       Date:  2020-07-09       Impact factor: 6.598

Review 9.  A Review about Regulatory Status and Recent Patents of Pharmaceutical Co-Crystals.

Authors:  Arun Kumar; Sandeep Kumar; Arun Nanda
Journal:  Adv Pharm Bull       Date:  2018-08-29

Review 10.  Three-dimensional electron microscopy techniques for unravelling mitochondrial dysfunction in heart failure and identification of new pharmacological targets.

Authors:  Hussam M Daghistani; Bodour S Rajab; Ashraf Kitmitto
Journal:  Br J Pharmacol       Date:  2018-10-25       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.